Overview

Bisoprolol in DMD Early Cardiomyopathy

Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This study aimed to use cardiac magnetic resonance imaging (CMR) to evaluate the efficacy and safety of bisoprolol therapy for boys with Duchenne muscular dystrophy(DMD) and preserved ejection fraction. On top of angiotensin-converting enzyme inhibitor (ACEI) , half of the participants will receive bisoprolol in combination, while the other half will not receive any beta-blocker.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Peking Union Medical College Hospital
Collaborators:
Chinese Academy of Medical Sciences
National Natural Science Foundation of China
Treatments:
Bisoprolol